The 19th Annual Mount Sinai Inflammatory Bowel Disease Consultants Course: Novel Therapies and Strategies

Friday, June 2, 2023, 7:30 AM - 3:30 PM, Icahn Medical Institute, Goldwurm Auditorium, 1425 Madison Avenue, New York, NY


The 19th Annual Mount Sinai Inflammatory Bowel Diseases Consultant’s Course is a Live Onsite course with Virtual Option. It will provide an in-depth review of strategies for participants to better diagnose, classify and achieve remission in patients with Crohn’s disease and ulcerative colitis. State-of-the-art lectures will be given by expert faculty on new medications approved for IBD, how therapy can be optimized, the treatment of fistula, how the disease can be monitored and debates concerning challenging clinical scenarios. This year’s course will focus on the new medications approved to treat IBD and how we can position and choose appropriate therapies. The goal is to help IBD caregivers and physicians meet the needs of our IBD patients by addressing sub-optimal disease control, appropriate choice of medications, and what treatment targets we should focus on. The Icahn School of Medicine at Mount Sinai course directors have selected experts in this field to lend their expertise to highlight the latest advances in the treatment to a disease that affects about 3.0 million people in the US.

1. Describe the use and adverse events associated with ozanimod, risankizumab, and upadacitinib.
2. Describe treatment options for special populations including pregnant patients, and patients with penetrating sequalae.
3. Describe appropriate implementation of therapeutic drug monitoring and treat-to-target approaches in clinical practice.
4. Identify the rationale for positioning of biologic therapies for Crohn’s disease and ulcerative colitis.

The Icahn School of Medicine at Mount Sinai is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

AMA PRA Category 1 Credits™ (6.75 hours), Non-Physician Attendance (6.75 hours)

It is the policy of the Icahn School of Medicine at Mount Sinai to ensure objectivity, balance, independence, transparency, and scientific rigor in all CME-provided educational activities. All faculty participating in the planning or implementation of a provided activity are expected to disclose to the audience any relevant financial relationships and to assist in resolving any conflict of interest that may arise from the relationship. Presenters must also make a meaningful disclosure to the audience of their discussions of unlabeled or unapproved drugs or devices. This information will be available as part of the course material.

Mitigation of Relevant Financial Relationships

Icahn School of Medicine at Mount Sinai adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CE activity, including faculty, planners, reviewers or others are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Friday, June 2, 2023

For sponsorship opportunities email [email protected]